AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31595300 — intervention group
Group type: COMPARATOR
Intervention: Contact-control intervention (CC)
Number of subjects: 208
Study 31556650 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavioral treatments (TF-CBT)
Number of subjects: 702
Study 31556650 — intervention group
Group type: COMPARATOR
Intervention: Present-Centered Therapy (comparison arm in 2 trials)
Number of subjects: 702
Study 28424222 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Balloon (PEB) angioplasty and stenting
Number of subjects: 155
Study 28424222 — intervention group
Group type: COMPARATOR
Intervention: Plain Balloon Angioplasty (BA) and stenting
Number of subjects: 155
Study 28424222 — intervention group
Group type: COMPARATOR
Intervention: Directional Atherectomy (DA) with distal protection and bailout stenting
Number of subjects: 155
Study 28424222 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 155
Study 25884986 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace Walk‐to‐Work promoters providing materials and support over 10 weeks.
Number of subjects: 0
Study 25884986 — intervention group
Group type: COMPARATOR
Intervention: Usual practice in control workplaces.
Number of subjects: 0
Study 23948637 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRI)
Number of subjects: 128
Study 20652755 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 671
Study 20652755 — intervention group
Group type: COMPARATOR
Intervention: No axillary dissection
Number of subjects: 671
Study 19218250 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior sub-Tenon capsule injection of triamcinolone acetonide (PSTA) 20 mg
Number of subjects: 41
Study 19218250 — intervention group
Group type: COMPARATOR
Intervention: No injection (Control)
Number of subjects: 41
Study 17641814 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback (vibration pulse to the trigeminal distribution on the forehead)
Number of subjects: 39
Study 17641814 — intervention group
Group type: COMPARATOR
Intervention: No vibrotactile feedback (control condition)
Number of subjects: 39
Study 14632810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae suspension
Number of subjects: 56
Study 14632810 — intervention group
Group type: COMPARATOR
Intervention: Buffer solution (placebo)
Number of subjects: 56
Study 10381711 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Check and Play It Safe (n=497)
Number of subjects: 997
Study 10381711 — intervention group
Group type: COMPARATOR
Intervention: Play It Safe alone (control group, n=500)
Number of subjects: 997
Study 8740332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine alone
Number of subjects: 0
Study 8740332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine in combination with cisplatin
Number of subjects: 0
Study 8740332 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 0
Study 2065534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum amnioinfusion for replacement (IAR) with normal saline solution
Number of subjects: 177
Study 2065534 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 177
Study 6627827 — intervention group
Group type: COMPARATOR
Intervention: 5 gm activated charcoal every 2 hr for 6 doses
Number of subjects: 6
Study 6627827 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 gm activated charcoal every 2 hr for 6 doses
Number of subjects: 6
Study 6627827 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 gm activated charcoal every 4 hr for 3 doses
Number of subjects: 6
Study 6627827 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 gm activated charcoal every hr
Number of subjects: 6
Study 3909842 — intervention group
Group type: EXPERIMENTAL
Intervention: gelatin 5.5 pc
Number of subjects: 18
Study 3909842 — intervention group
Group type: COMPARATOR
Intervention: serum protein solution
Number of subjects: 18
Study 28836577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 83
Study 28836577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 27521283 — intervention group
Group type: EXPERIMENTAL
Intervention: DADDS-G (Death and Dying Distress Scale)
Number of subjects: 77
Study 24796045 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome-differentiation acupuncture
Number of subjects: 105
Study 24796045 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular acupuncture
Number of subjects: 105
Study 24796045 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint group
Number of subjects: 105
Study 22607867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 1012
Study 22607867 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 1012
Study 20817410 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTP (Alcohol Skills Training Program)
Number of subjects: 204
Study 20817410 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 204
Study 20817410 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTP for mandated students
Number of subjects: 204
Study 20817410 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary sample
Number of subjects: 204
Study 18161760 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 40
Study 18161760 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic inspection only
Number of subjects: 40
Study 15832634 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract analogy to specific training items
Number of subjects: 0
Study 15832634 — intervention group
Group type: COMPARATOR
Intervention: Surface characteristics of items
Number of subjects: 0
Study 15832634 — intervention group
Group type: COMPARATOR
Intervention: Grammaticality
Number of subjects: 0
Study 12788175 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postmastectomy radiotherapy (RT)
Number of subjects: 656
Study 12788175 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (Control)
Number of subjects: 656
Study 15493096 — intervention group
Group type: EXPERIMENTAL
Intervention: Word identification training (35 hours)
Number of subjects: 166
Study 15493096 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive phonics program
Number of subjects: 166
Study 15493096 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological training program
Number of subjects: 166
Study 15493096 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological deficits
Number of subjects: 166
Study 9003465 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin 90 and 180 mg daily for 60 days
Number of subjects: 30
Study 9003465 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 30
Study 9003465 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin 10 and 30 mg daily for 60 days
Number of subjects: 30
Study 1289676 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUS-guided systematic random biopsy (TRUSPNB)
Number of subjects: 100
Study 1289676 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE, TRUS, TRUSPNB
Number of subjects: 100
Study 6748872 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-Ag positive group (24 patients always delta-Ag positive and 2 became delta-Ag positive during observation)
Number of subjects: 45
Study 6748872 — intervention group
Group type: COMPARATOR
Intervention: Delta-Ag negative group (10 patients always delta-Ag negative and 9 became delta-Ag negative during the study)
Number of subjects: 45
Study 6748872 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone treatment (15 mg daily)
Number of subjects: 45
Study 30641146 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Adherence Pathway (AAP) application with electronic adherence monitors
Number of subjects: 39
Study 30641146 — intervention group
Group type: COMPARATOR
Intervention: Control group (not monitored for MF/F adherence)
Number of subjects: 39
Study 29939895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (TXA)
Number of subjects: 156
Study 29939895 — intervention group
Group type: COMPARATOR
Intervention: Control (no TXA)
Number of subjects: 156
Study 27576483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of etanercept and fumarates
Number of subjects: 33
Study 27576483 — intervention group
Group type: COMPARATOR
Intervention: Etanercept monotherapy
Number of subjects: 33
Study 24447116 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity (HI) home visitation coaching program (55 sessions)
Number of subjects: 361
Study 24447116 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity (LI) condition (monthly phone calls, printed materials, community referrals)
Number of subjects: 361
Study 22962863 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention
Number of subjects: 146
Study 22962863 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study 19925875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus high-dose corticosteroids
Number of subjects: 32
Study 18574157 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with fluorouracil, cisplatin, and paclitaxel followed by fluorouracil plus paclitaxel with 50.4 Gy of radiation (arm A)
Number of subjects: 84
Study 18574157 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with paclitaxel plus cisplatin followed by the same chemotherapy with 50.4 Gy of radiation (arm B)
Number of subjects: 84
Study 16013780 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional counselling by paramedics
Number of subjects: 174
Study 16013780 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnostic procedure (Control)
Number of subjects: 174
Study 12453928 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. bupivacaine (5 mg ml(‐1)) 1 mg kg(‐1)
Number of subjects: 60
Study 12453928 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. lidocaine (100 mg ml(‐1)) 2 mg kg(‐1)
Number of subjects: 60
Study 12453928 — intervention group
Group type: COMPARATOR
Intervention: i.m. saline 5 ml
Number of subjects: 60
Study 10703901 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (2 l NaCl 0.9% over 2 h) during high salt (HS) diet
Number of subjects: 39
Study 10703901 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (2 l NaCl 0.9% over 2 h) during low salt (LS) diet
Number of subjects: 39
Study 10703901 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (2 l NaCl 0.9% over 2 h)
Number of subjects: 39
Study 8794966 — intervention group
Group type: EXPERIMENTAL
Intervention: C31G rinse
Number of subjects: 20
Study 8794966 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 20
Study 8794966 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC rinses
Number of subjects: 20
Study 8794966 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride paste
Number of subjects: 20
Study 8794966 — intervention group
Group type: COMPARATOR
Intervention: Minus CPC control rinse
Number of subjects: 20
Study 8794966 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo control)
Number of subjects: 20
Study 1743373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream (pretreated side)
Number of subjects: 5
Study 1743373 — intervention group
Group type: COMPARATOR
Intervention: Non-pretreated side (control)
Number of subjects: 5
Study 7072476 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg in 10 ml saline
Number of subjects: 14
Study 7072476 — intervention group
Group type: COMPARATOR
Intervention: 10 ml saline (control)
Number of subjects: 14
Study 7072476 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg in saline (if pain score exceeded 5)
Number of subjects: 14
Study 7072476 — intervention group
Group type: COMPARATOR
Intervention: Saline (if pain score exceeded 5)
Number of subjects: 14
Study 7072476 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 14
Study 7072476 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 14
Study 30991969 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly injectable formulation (AOM)
Number of subjects: 193
Study 27637407 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive management (active intervention)
Number of subjects: 102
Study 27637407 — intervention group
Group type: COMPARATOR
Intervention: Ordinary management (control)
Number of subjects: 102
Study 25879016 — intervention group
Group type: EXPERIMENTAL
Intervention: CHG-impregnated dressing
Number of subjects: 308
Study 25879016 — intervention group
Group type: COMPARATOR
Intervention: Conventional draping
Number of subjects: 308
Study 22744704 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐PAS with 50 ms ISI
Number of subjects: 0
Study 22744704 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive laser pulses and rTMS
Number of subjects: 0
Study 22744704 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐PAS with laser pulses ipsilaterally to M1
Number of subjects: 0
Study 22744704 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS after Laser‐PAS
Number of subjects: 0
Study 22744704 — intervention group
Group type: EXPERIMENTAL
Intervention: TES after Laser‐PAS
Number of subjects: 0
Study 22744704 — intervention group
Group type: COMPARATOR
Intervention: Memantine (NMDA receptor antagonist)
Number of subjects: 0
Study 22744704 — intervention group
Group type: COMPARATOR
Intervention: α‐lipoic acid (placebo)
Number of subjects: 0
Study 18829205 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin aspart every 2 h until BG < 200 mg/dL
Number of subjects: 54
Study 18829205 — intervention group
Group type: COMPARATOR
Intervention: Historical controls with DM and an ED admission BG > 200 mg/dL
Number of subjects: 54
Study 19515731 — intervention group
Group type: EXPERIMENTAL
Intervention: Large bite size (approximately 15 g)
Number of subjects: 22
Study 19515731 — intervention group
Group type: COMPARATOR
Intervention: Small bite size (approximately 5 g)
Number of subjects: 22
Study 19515731 — intervention group
Group type: EXPERIMENTAL
Intervention: Free OPT
Number of subjects: 22
Study 19515731 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT of 3 s
Number of subjects: 22
Study 17083378 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week therapy with omeprazole, amoxicillin, and clarithromycin
Number of subjects: 486
Study 17083378 — intervention group
Group type: COMPARATOR
Intervention: 1-week therapy with omeprazole, amoxicillin, and clarithromycin
Number of subjects: 486
Study 15010386 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern radiotherapy techniques
Number of subjects: 62
Study 11393609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation
Number of subjects: 0
Study 11393609 — intervention group
Group type: COMPARATOR
Intervention: Litigation
Number of subjects: 0
Study 9269069 — intervention group
Group type: EXPERIMENTAL
Intervention: Random donor platelet (RDP) transfusion
Number of subjects: 2
Study 8329794 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 20
Study 8329794 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 20
Study 8329794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 20
Study 2885767 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (nonionic low-osmolal contrast medium)
Number of subjects: 18
Study 2885767 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate (ionic high-osmolal contrast medium)
Number of subjects: 18
Study 29604186 — intervention group
Group type: EXPERIMENTAL
Intervention: Baminercept (100 mg subcutaneous injections every week for 24 weeks)
Number of subjects: 52
Study 29604186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching injections)
Number of subjects: 52
Study 29604186 — intervention group
Group type: EXPERIMENTAL
Intervention: Baminercept
Number of subjects: 52
Study 29604186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 27709863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 30
Study 27709863 — intervention group
Group type: COMPARATOR
Intervention: Steroid (TA) injection
Number of subjects: 30
Study 27709863 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid (TA) injection (first)
Number of subjects: 30
Study 27709863 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) injection (first)
Number of subjects: 30
Study 27709863 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid (TA) first, Hyaluronic acid (HA) later
Number of subjects: 30
Study 27709863 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) first, Steroid (TA) later
Number of subjects: 30
Study 26010325 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate restriction (non-chocolate snacks provided for 3 weeks)
Number of subjects: 56
Study 26010325 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-restriction period
Number of subjects: 56
Study 26010325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-restriction periods
Number of subjects: 56
Study 24314204 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief personalized feedback intervention materials
Number of subjects: 185
Study 24314204 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 185
Study 21076997 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative transportation strategy during the Olympic Games
Number of subjects: 0
Study 21076997 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (1-30 June)
Number of subjects: 0
Study 21076997 — intervention group
Group type: COMPARATOR
Intervention: Pre-Olympic period
Number of subjects: 0
Study 21076997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative ozone concentrations of 70 to 100 ppb and 100 ppb or more
Number of subjects: 0
Study 19340896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs) including amitriptyline, imipramine, desipramine, doxepin, and trimipramine
Number of subjects: 7
Study 19340896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 7
Study 19340896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 16764963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based prompt intervention
Number of subjects: 1176
Study 15504191 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 microg kg(‐1) and atropine 40 microg kg(‐1); group C, n = 48)
Number of subjects: 100
Study 15504191 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (300 microg kg(‐1) and atropine 40 microg kg(‐1); group M, n = 52)
Number of subjects: 100
Study 11300388 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural solution with fentanyl (SBAF)
Number of subjects: 42
Study 11300388 — intervention group
Group type: COMPARATOR
Intervention: Epidural solution without fentanyl (SBA)
Number of subjects: 42
Study 11300388 — intervention group
Group type: COMPARATOR
Intervention: Propofol anaesthesia and epidural solution without fentanyl (PBA)
Number of subjects: 42
Study 9131364 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-coated catheters
Number of subjects: 221
Study 9131364 — intervention group
Group type: COMPARATOR
Intervention: Uncoated catheters
Number of subjects: 221
Study 7890063 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (estradiol)
Number of subjects: 40
Study 7890063 — intervention group
Group type: EXPERIMENTAL
Intervention: P (progesterone)
Number of subjects: 40
Study 7890063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of E2 and P
Number of subjects: 40
Study 7890063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2795526 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic training programme
Number of subjects: 47
Study 2795526 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo strength and flexibility training programme
Number of subjects: 47
Study 342295 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate 0.1% cream
Number of subjects: 0
Study 342295 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate 0.1% ointment
Number of subjects: 0
Study 342295 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate 0.1% fatty ointment
Number of subjects: 0
Study 342295 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide 0.025% ointment
Number of subjects: 0
Study 342295 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide 0.025% cream
Number of subjects: 0
Study 31319510 — intervention group
Group type: EXPERIMENTAL
Intervention: Anserine/Carnosine Supplementation (750 mg of anserine and 250 mg of carnosine per day)
Number of subjects: 54
Study 31319510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31319510 — intervention group
Group type: EXPERIMENTAL
Intervention: Anserine/Carnosine Supplementation (750 mg of anserine and 250 mg of carnosine per day) in APOE4 (+) subjects
Number of subjects: 54
Study 28690011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus pemetrexed/cisplatin
Number of subjects: 450
Study 28690011 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pemetrexed/cisplatin
Number of subjects: 450
Study 28690011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib maintenance treatment
Number of subjects: 450
Study 28690011 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance treatment
Number of subjects: 450
Study 25397860 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing the quit plan (CBT)
Number of subjects: 76
Study 25397860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking practice of letting urges pass (ACT)
Number of subjects: 76
Study 25397860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking ACT skill practice
Number of subjects: 76
Study 26221044 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% W max aerobic training intensity (group 1, n = 17)
Number of subjects: 34
Study 26221044 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% W max aerobic training intensity (group 2, n = 17)
Number of subjects: 34